SALT LAKE CITY, Utah, March 23, 2016 /PRNewswire/ --
TheStockRadio.com, which is dedicated to disseminating "real news" from growing companies, announced today that it has conducted an interview with Dr. Robert Clarke, CEO of Boston-based pharmaceutical company, Pulmatrix, Inc. (NASDAQ: PULM).
The full interview and profile can be viewed here: http://thestockradio.com/pulm-audio-interview-2933.html
As Dr. Clarke described in the interview, Pulmatrix uses an approach, originally pioneered at Harvard and the Massachusetts Institute of Technology, that represents a major advancement in delivering drugs to the lungs of patients with pulmonary disease.
"The focus of the company is on diseases of great unmet medical needs, such as cystic fibrosis and chronic obstructive pulmonary disease (COPD)," said Dr. Clarke.
Pulmatrix's unique technology is an engineered dry powder, called iSPERSE, that patients can easily inhale, carrying crucial drugs deep into the airways in patients' lungs. That's a sharp contrast to current products, where much of the drug being inhaled never makes it to the lungs where it's needed. Typically, "patients end up with more of the drug in their throat than in their lungs, which can lead to side effects that are undesirable," Dr. Clarke explained. It also wastes a lot of the drug.
The Pulmatrix iSPERSE technology is far more efficient than current inhalers, enabling Pulmatrix to get the same benefit with fewer side effects and 80 percent less of the drug. In addition, the particles fly so easily deep into the lungs that patients can get the dose they need even when they have trouble breathing in. "These patients are on a long decline in pulmonary function," said Dr. Clarke. "The worse the disease, the harder and harder it is to breath." Pulmatrix's iSPERSE solves this problem. "That's why we are so passionate about this," said Dr. Clarke. "Patients can get the dose they need even on their worst days."
The delivery technology also opens up important new avenues for treatment. Fungal infections in are a major problem in cystic fibrosis. But the only current treatments are oral or IV anti-fungal drugs that must be given in high doses in order to bring the drug to the lungs to fight the infection-and even very high doses (with serious side effects) may not be enough to wipe out the fungus.
Pulmatrix's lead drug uses iSPERSE technology to deliver the anti-fungal drug right to the site of the infection-the lungs. "We get very high levels of the drug in the lung tissue," said Dr. Clarke. "It will eradicate the fungus. And because we control the particle size, we can keep most of the drug out of the bloodstream." Side effects should thus be minimal.
"This is a great advantage," said Dr. Clarke. "We think it will translate to better efficacy and dose profile, and better quality of life."
Dr. Clarke said that the company is planning to bring both products to the market "in the coming years" and is already working on a treatment for another disease, idiopathic pulmonary fibrosis (IPF).